NUVB
Nuvation Bio Inc.About NUVB
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Cylvex Score
Some risk factors elevated
Multi-factor score. Not a buy/sell signal.
Score history
CalibratingScore history appears after more daily scores
What goes into the score
6 axes · equal weightThe Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.